Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00772-9/fulltext